Media ReleasesINOVIQ

View All INOVIQ News

INOVIQ completes $7m placement

-- INOVIQ successfully completed a A$7 million placement to institutional and sophisticated investors1 at A$0.50 per share.
-- INOVIQ Board and Management have participated in the placement.2
-- Funds raised will be used to advance commercialisation of EXO-NET research tools and SubB2M diagnostics, progress development of pipeline diagnostics and expedite research of high-value cancer therapeutics, enabling the Company to progress its pipeline and bring new products to market.
-- Shareholders in Australia and New Zealand will be offered the opportunity to participate in a share purchase plan to raise up to a further A$2 million with the capacity for oversubscriptions of up to A$0.4 million at the Company's discretion (subject to the Company’s placement capacity) on similar terms as the placement.
-- INOVIQ’s expected proforma net cash balance will be approximately $12.7 million post placement and SPP3.

Melbourne, Australia, 12 June 2024: INOVIQ Limited (ASX: IIQ) (INOVIQ or the Company), a company focused on developing next generation cancer diagnostics and therapeutics, has completed a placement to institutional and sophisticated investors4, to raise approximately A$7.0 million (before costs) under a placement of 14 million new fully paid ordinary shares in the Company (Shares) at A$0.50 per Share (Placement), with one free quoted option for every two new Shares issued under the Placement with an option exercise price of A$1.00 and an exercise period of two years. The pricing of the Placement represents an 11.5% discount to the last traded market price.

For more information, download the attached PDF.

Download this document

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?